Natsar Pharmaceuticals, Inc. — SEC Form D Filing
Natsar Pharmaceuticals, Inc. filed an SEC Form D on May 8, 2026, reporting $4.22M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- May 8, 2026
- Amount reported
- $4.22M
- Round stage
- Seed
- Industry
- Pharmaceuticals
- Website
- https://www.natsarpharmaceuticals.com/
What the company does
Securities: Equity. Revenue: No Revenues. Exemption: Rule 506(b). Incorporated: DELAWARE
Problem
DDX3 is overexpressed in many cancer types and is associated with lower survival rates in patients with diseases such as lung cancer.
Solution
Natsar Pharmaceuticals is developing a DDX3 inhibitor, RK-33, designed to impede DDX3 function, thereby inducing apoptosis and promoting radiation sensitization in cancer cells to treat conditions like lung, brain, and breast cancer, among others.
Verdict
Investors approved Natsar Pharmaceuticals' narrative primarily due to the urgency surrounding cancer treatment advancements, a clear focus on DDX3's role in survival rates, and the potential of RK-33 as a targeted therapy. This cleared because the technology targets a critical biological mechanism, not because the company presented a fully fleshed-out commercial strategy. However, the limited upside lies in the high failure rate typical of drug development and the uncertain market access given competitive oncology treatments.
Source: SEC EDGAR Form D filing